Difference between revisions of "Alitretinoin (Panretin)"
Jump to navigation
Jump to search
m (→Also known as) |
|||
| Line 12: | Line 12: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code names:''' | + | *'''Code names:''' ALRT-1057, LGD-1057 |
*'''Brand names:''' Panretin, Panretyn, Panrexin | *'''Brand names:''' Panretin, Panretyn, Panrexin | ||
Latest revision as of 02:06, 11 August 2023
Mechanism of action
From the NCI Drug Dictionary: An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.
Diseases for which it is used
Patient Drug Information
History of changes in FDA indication
- 1999-02-02: Initial approval for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. (Based on Walmsley et al. 1999 & Bodsworth et al. 2001)
Also known as
- Code names: ALRT-1057, LGD-1057
- Brand names: Panretin, Panretyn, Panrexin